Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Remote Patient Monitoring with Digital Medicine Society

The Digital Medicine Society (DiMe) is a global nonprofit specializing in the advancement of ethical, effective, equitable, and safe use of digital technology for redefining healthcare and optimizing lives. Jennifer Goldsack, CEO of DiMe, spoke with Intel’s Head of Global Health Solutions Alex Flores on the advancements in remote patient monitoring and the role…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The Digital Medicine Society (DiMe) is a global nonprofit specializing in the advancement of ethical, effective, equitable, and safe use of digital technology for redefining healthcare and optimizing lives. Jennifer Goldsack, CEO of DiMe, spoke with Intel’s Head of Global Health Solutions Alex Flores on the advancements in remote patient monitoring and the role technology plays in this.

Remote patient monitoring allows parsing out different digital phenotypes within certain disease states to effectively match treatment with the patient. Goldsack says, “In those broad disease states, where there’s very little that we can do to either ameliorate symptoms of the disease or cure the disease — something like Parkinson’s or Alzheimer’s disease. We’re hopeful that these new measures can start to advance the field.”

Goldsack believes there is a much more practical reason for remote patient monitoring to become an essential focus of care: the evolving role and methods of healthcare today.

“We must start thinking about how we can start to monitor people’s health outside the clinic walls,” she explains. “How can we think about patients with complex chronic diseases who may have episodic conditions with flare-ups? How can we monitor their well-being and health performance under clinicians’ care without bringing them into the hospital every time?”

The reality that healthcare presently faces is a shortage of doctors and clinicians to treat the number of patients. Remote patient care is one healthcare solution that helps ensure the patient gets the best care possible, even with reduced resources available. “We can use remote patient monitoring to get early signals… [and] we can intervene and care for them before those outcomes become bad and before they become pricey,” Goldsack says.

The technology behind remote patient monitoring must be high quality to make high-quality clinical decisions. Clinical validation of the gathered data is vital in this process. Goldsack says it’s also crucial that the technology deployed is an affordable solution, because if it isn’t, then it won’t be sustainable.

In terms of utilizing AI in the remote patient monitoring process, Goldsack says there is unlimited potential. Still, it is important to keep things in perspective and focus on the most critical challenges first. “We should look at the ability to identify particular phenotypes within large population-level data sets,” she notes. “AI might be able to tell us if we deliver the right data that some patients do well, and for whatever reasons, some patients end up having a fall and an injury and come back into the hospital within four weeks. It might be that we have no idea what the differences are between those patients who fall and those who don’t.” AI could help make those determinations.

Learn more about remote patient monitoring by connecting with Jennifer Goldsack or Alex Flores on LinkedIn or visit: 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Health and Life Sciences at the Edge.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512